慢性乙型肝炎患者代谢合并症与肝脏相关事件的相关性
该回顾性队列研究纳入1850例慢性乙型肝炎患者,评估超重、糖尿病、高血压和血脂异常等代谢合并症与肝脏相关事件的关系。中位随访7.3年,共记录111例首次事件。高血压(HR 8.3)、糖尿病(HR 5.4)、血脂异常(HR 2.8)和超重(HR 1.7)均与肝脏相关事件风险增加相关,多种合并症并存时风险进一步升高。
要点
- 高血压(HR 8.3)、糖尿病(HR 5.4)、血脂异常(HR 2.8)、超重(HR 1.7)均与肝脏相关事件风险增加相关。
- 代谢合并症数量越多,肝脏相关事件风险越高。
- 在肝硬化与非肝硬化、HBeAg阴性且HBV DNA<2000 IU/mL等亚组中结果一致。
核心结论
- 慢性乙型肝炎患者的代谢合并症与肝脏相关事件风险增加相关,多种合并症并存时风险最高;研究结果在多个临床相关亚组中一致,强调对慢性乙型肝炎患者进行全面的代谢评估的必要性。
研究设计与样本
- 回顾性队列研究,纳入荷兰鹿特丹Erasmus MC大学医学中心和加拿大多伦多总医院接受肝活检的慢性乙型肝炎患者,共分析1850例。
- 代谢合并症(超重、糖尿病、高血压、血脂异常)基于病历回顾评估;主要终点为肝脏相关事件,定义为肝细胞癌、肝移植或肝脏相关死亡的首个复合终点。
主要发现
- 926例(50.1%)超重,161例(8.7%)有高血压,116例(6.3%)有血脂异常,82例(4.4%)有糖尿病。
- 中位随访7.3年(四分位距2.9-11.5年)期间,共记录111例首次事件。
- 高血压(HR 8.3;95%CI 5.5-12.7)、糖尿病(HR 5.4;95%CI 3.2-9.1)、血脂异常(HR 2.8;95%CI 1.6-4.8)和超重(HR 1.7;95%CI 1.1-2.5)与肝脏相关事件风险增加相关。
- 多种合并症并存进一步增加风险。
- 在肝硬化与非肝硬化患者中、在HBeAg阴性且HBV DNA低于2000 IU/mL的非肝硬化患者中,以及在校正年龄、性别、种族、HBeAg状态、HBV DNA、抗病毒治疗使用和肝硬化存在的多变量分析中,结果一致。
临床怎么用
- 原文结论强调对慢性乙型肝炎患者进行全面的代谢评估的必要性,未给出具体推荐条款。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with chronic hepatitis B (CHB) are at increased risk of hepatocellular carcinoma and (liver-related) mortality. In addition to hepatitis B-related factors, metabolic comorbidities may contribute to the progression of fibrosis. Therefore, we studied the association between metabolic comorbidities and adverse clinical outcomes in patients with CHB. METHODS: We conducted a retrospective cohort study of CHB patients attending the Erasmus MC University Medical Center (Rotterdam, The Netherlands) and CHB patients who underwent liver biopsy at the Toronto General Hospital (Toronto, Canada). The presence of metabolic comorbidities (ie, overweight, diabetes mellitus, hypertension, and dyslipidemia) was assessed based on chart review. The primary end point was liver-related events, defined as the first composite of hepatocellular carcinoma, liver transplantation, or liver-related mortality. RESULTS: We analyzed 1850 patients, of whom 926 (50.1%) were overweight, 161 (8.7%) had hypertension, 116 (6.3%) had dyslipidemia, and 82 (4.4%) had diabetes. During a median follow-up period of 7.3 years (interquartile range, 2.9-11.5 y), a total of 111 first events were recorded. Hypertension (hazard ratio [HR], 8.3; 95% CI, 5.5-12.7), diabetes (HR, 5.4; 95% CI, 3.2-9.1), dyslipidemia (HR, 2.8; 95% CI, 1.6-4.8), and overweight (HR, 1.7; 95% CI, 1.1-2.5) were associated with an increased risk for liver-related events. The presence of multiple comorbidities further increased the risk. Findings were consistent for patients with and without cirrhosis, among noncirrhotic hepatitis B e antigen-negative patients with hepatitis B virus DNA less than 2000 IU/mL and in multivariable analysis adjusting for age, sex, ethnicity, hepatitis B e antigen status, hepatitis B virus DNA, use of antiviral therapy, and the presence of cirrhosis. CONCLUSIONS: Metabolic comorbidities in CHB patients are associated with an increased risk for liver-related events, with the highest risk observed in patients with multiple comorbidities. Findings were consistent in various clinically relevant subgroups, underscoring the need for thorough metabolic assessment in patients with CHB.
引用
- Patmore LA, Katwaroe WK, van der Spek D, et al. Association Between the Presence of Metabolic Comorbidities and Liver-Related Events in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2023. PMID: 37004973. doi:10.1016/j.cgh.2023.03.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。